Stock of the Day

June 12, 2025

EyePoint Pharmaceuticals (EYPT)

$9.03
+$0.17 (+1.9%)
Market Cap: $621.36M

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EyePoint Pharmaceuticals Bull Case

Here are some ways that investors could benefit from investing in EyePoint Pharmaceuticals, Inc.:

  • EyePoint Pharmaceuticals, Inc. has a promising product pipeline, particularly with EYP-1901, which is in Phase 2 clinical trials for treating serious retinal diseases such as wet age-related macular degeneration, non-proliferative diabetic retinopathy, and diabetic macular edema. Successful outcomes could lead to significant market opportunities.
  • The company reported revenue of $24.50 million in the latest quarter, significantly exceeding analyst estimates of $8.84 million, indicating strong market demand and operational performance.
  • Analysts have a generally positive outlook on the stock, with an average rating of "Moderate Buy" and a target price of $25.38, suggesting potential for price appreciation.
  • EyePoint Pharmaceuticals, Inc. utilizes proprietary Durasert E technology for sustained drug delivery, which could provide a competitive edge in the biopharmaceutical market.
  • The current stock price is positioned at a level that may attract investors looking for growth opportunities in the biopharmaceutical sector, especially given the company's innovative approach to treating retinal diseases.

EyePoint Pharmaceuticals Bear Case

Investors should be bearish about investing in EyePoint Pharmaceuticals, Inc. for these reasons:

  • The company has a negative net margin of 226.57%, indicating that it is currently spending significantly more than it earns, which could raise concerns about financial sustainability.
  • EyePoint Pharmaceuticals, Inc. reported a negative return on equity of 43.01%, suggesting that the company is not generating sufficient profit relative to shareholder equity, which may deter potential investors.
  • Despite the positive revenue report, the company is still in the clinical stage, meaning that there is inherent risk associated with the success of its product candidates and their eventual market approval.
  • One investment analyst has rated the stock with a sell rating, which could indicate potential risks or concerns that may not be fully addressed by the broader analyst community.
  • Market volatility and competition in the biopharmaceutical sector could impact the company's growth prospects and stock performance, making it a riskier investment choice.

Breakout Momentum Plays You May Not Know About

Written By Nathan Reiff on 6/6/2025

Breakout Rack: Momentum Stocks - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.

High volatility has plagued markets throughout much of 2025. While many consider this a bad thing, particularly when trends point downward, it can also create opportunities for momentum investors to capture gains when target stocks are up. Of course, timing a momentum play can be easier said than done.

Regarding momentum investing, traders may have an advantage if they can identify targets early in a sustained rally and, potentially, if those stocks are relatively unknown by the broader investing community.

Three such companies, two small-cap firms and one slightly larger in a niche segment of a popular industry, have trended upward recently and may be worth closer consideration by investors seeking the next momentum target.

Promising Clinical Trial Data Drives EyePoint Rally

First up is EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), a clinical-stage biopharma firm developing treatments for patients with retinal diseases. In May, EyePoint reported results for the first quarter of the year, including top-line performance that shattered analyst expectations.

While forecasts had called for revenue of just under $9 million, EyePoint generated nearly $25 million in the first months of the year. The company posted losses per share in line with analyst predictions; like many clinical-stage pharmaceutical firms, sustained profitability remains elusive pending the success of one or more commercially viable drug candidates.

The company is getting closer to that milestone all the time. Its lead drug candidate, DURAVYU, recently exceeded enrollment for a critical Phase 3 clinical trial, and EyePoint expects top-line data from the trial in 2026. DURAVYU is a candidate for treatment of wet age-related macular degeneration, but EyePoint also sees potential for its use in diabetic macular edema. EyePoint ended the first quarter with more than $318 million in cash and investments, sufficient to sustain operations through 2027.

EYPT shares are up more than 19% in the last month, and based on a consensus price estimate of $25.38, analysts expect growth is just beginning; this estimate would suggest the price of EYPT stock could more than triple from current levels.

Crucial Semiconductor Manufacturing Systems Keep Nova Essential

Nova Ltd. (NASDAQ: NVMI) designs and builds process control systems used in the manufacturing of semiconductors, making it an essential part of a highly popular industry. Nova has also offered stellar earnings results this year, with quarterly revenue rising by more than 50% year-over-year (YOY) in the first months of the year, topping analyst predictions. Earnings per share (EPS) of $2.18 beat analyst estimates by 10 cents.

This momentum is expected to continue, as analysts suggest Nova's earnings growth could be more than 7% in the future.

Nova also has noteworthy cash flow improvement; YOY cash flow growth is about 32%, helping to ensure it has ample room to scale up operations, expand its offerings, or buy back shares.

NVMI shares have climbed by more than 10% in the last month, and again, analysts expect this growth to continue. With a consensus price target of $277, NVMI could have upside potential of over 27%. Four out of five analysts rating NVMI shares have assigned it a Buy, signaling widespread optimism.

Leading LiDAR Tech Brings Major Partnerships and Growth for Ouster

Ouster Inc. (NYSE: OUST) provides LiDAR technology for 3D mapping and imaging. This makes the company a vital partner for other companies in the robotics, automation, and automotive industries, among many others. The critical nature of Ouster's technological offerings has led to numerous recent partnerships, including with construction and heavy machinery builder Komatsu, German manufacturing firm LASE PeCo, and others.

Ouster's $33 million in revenue for the first quarter beat earnings estimates and climbed by 26% YOY, and GAAP gross margin of 41% improved significantly over 29% one year prior. Perhaps most importantly for future momentum, the company projects between $32 million and $35 million in second-quarter revenue, highlighting major upside potential. All seven analysts reviewing OUST shares have provided a Buy rating.

Ouster has experienced a more significant rally than either company above, climbing by more than 71% in the last year. Analysts still view the possibility of additional upside, although investors may need to act quickly. On the other hand, this firm may also be poised for long-term success given the increase in demand for robotics and automation services across multiple sectors.

Recent News